哮喘的中医辨证分型与外周微循环的关系

本文对不同辨证分型的哮喘患者进行了甲襞和舌尖微循环观察，探讨中医辨证分型与外周微循环的关系。结果表明：１３２例哮喘患者中除１６例甲臂襞微循环正常或大致正常外，基余患者均有不同程度的异常改变。     

中医药辨证论治对老年糖调节受损的治疗作用

目的:观察中医辨证分型用药对老年糖调节受损的治疗作用.方法:199例患者随机分为2组,治疗组132例,对照组67例,2组均严格按要求控制饮食,加强运动,治疗组同时辨证分型服用中药,全部病例均治疗6个月观察疗效.结果:治疗组有效率明显优于对照组(P<0.01).结论:对于西医尚无药治疗的糖调节受损,中医药可以通过辨证分型用药取得良好的效果.     

生脉注射液配合辨证施护治疗心律失常效果观察

目的:探讨生脉注射液配合辨证施护治疗心律失常的疗效.方法:将120例心律失常患者随机分为观察组和对照组各60例,对照组采用心律失常常规治疗护理;观察组在对照组的基础上加用生脉针及辨证施护,观察症状、体征、副作用及辨证分型.结果:生脉与辨证施护对主要症状改善程度较好, 按中医证类疗效比较:观察组有效55例,有效率91.67%,对照组有效37例,有效率61.67%.χ2=15.09,P<0.05.心电图疗效总有效率为90.00%.结论:生脉注射液配合辨证施护对心律失常主要症状的改善程度较好.可广泛应用于心律失常的治疗,可提高临床治疗效果,降低治疗副作用.     

中西医结合治疗冠状动脉粥样硬化性心脏病心房颤动116例临床观察

目的：观察中医辨证分型结合普罗帕酮与单用普罗帕酮治疗冠状动脉粥样硬化性心脏病（冠心病）心房颤动（房颤）的临床疗效,以及中西医结合的疗效与中医分型、中医证候的关系。方法：将１９４例冠心病房颤患者随机分为中医辨证分型结合普罗帕酮治疗组（治疗组,１１６例）和单用普罗帕酮对照组（对照组,７８例）,连续用药２０日,观察其疗效。结果：治疗组显效率（４６．５５％）及总有效率（９２．２４％）均明显优于对照组（３３     

中医辨证分型治疗斑秃70例疗效观察

目的探讨中医辨证分型治疗斑秃的临床疗效。方法选择2010-12—2012-06中医科诊治的斑秃患者140例,按随机数字法分为中药组70例和西药组70例,中药组采用中医辨证论治理论,按不同分型给予相应的中医药方进行治疗,西药组给予口服胱氨酸片、维生素B片。14 d为1个疗程,6个疗程观察疗效。结果中药组总有效率为92.9%,西药组总有效率为68.6%,中药组优于西药组。两组疗效情况比较,差异具有统计学意义（P〈0.05）。结论中医辨证分型治疗斑秃临床疗效满意,安全可靠,值得临床推广应用。     

中医辨证分型治疗皮肤瘙痒症62例疗效观察

目的探讨中医辨证分型治疗皮肤瘙痒症的临床疗效。方法选择2012-03—2013-03济南军区青岛第一疗养院中医科诊治的皮肤瘙痒症患者62例,采用中医辨证论治理论,按不同分型给予相应的中医药方进行治疗。15 d为1个疗程,4个疗程观察疗效。结果通过4个疗程的治疗后,取得了良好的效果,62例患者中痊愈38例,显效22例,无效2例,总有效率96.77%,两组患者在治疗期间均未出现任何明显不良反应。结论通过中医辨证施治的灵活手段,诸多中药的合用治疗皮肤瘙痒症临床疗效确切、持久,安全可靠,副作用小,复发率低。     

辨证分型治疗脑动脉硬化性眩晕症76例

目的 :观察运用中医辨证分型治疗脑动脉硬化性眩晕症的疗效。方法 :将 1 5 0例以眩晕为主要临床表现的脑动脉硬化病人 ,随机分为治疗组 76例和对照组 74例 ,治疗组按中医理论辨证分型 ( 5型 )治疗 ,对照组给予口服西药治疗 ,2组病例均以 2周为 1个疗程 ,连服 2个疗程后观察疗效 ;结果 :治疗组有效率 90 .8% ,对照组 74.3 % ,2组比较 ,P <0 .0 1。结论 :采用中医辨证分型治疗脑动脉硬化性眩晕症疗效明显优于使用西药     

《中国中西医结合急救杂志》2004年第11卷关键词索引（按首字汉语拼音音节及论文发表顺序为序）

崩漏 乌鸡白凤丸治疗漏下的疗效观察．卢漫芳，邱爱丽．(1)：31．辨证论治胃癌前病变环氧合酶一2蛋白的表达及中医辨证．甘爱华，许岸高，刘集鸿，赵玉刚．(1)：28．辨证分型老年严重脓毒症患者肾上腺皮质功能与中医证型的关系．吴海云，危成筠，朱广卿，许强．朱姝，王士雯．(3)：133．辨证分型治疗全身炎症反应综合征疗效观察．蒋超．     

中医辨证分型治疗过敏性紫癜50例疗效观察

目的探讨中医辨证分型治疗过敏性紫癜的临床疗效。方法选择2012-02—2013-02我院中医科诊治的过敏性紫癜患者100例,按随机数字法分为中药组50例和西药组50例,中药组采用中医辨证论治理论,按不同分型给予相应的中医药方进行治疗,西药组给予口服强的松、赛庚啶片、维生素C、芦丁片。15 d为1个疗程,4个疗程观察疗效。结果中药组总有效率为94%,西药组总有效率为76%,中药组优于西药组。两组疗效情况比较差异有统计学意义（P〈0.05）。结论中医辨证分型治疗过敏性紫癜临床疗效确切、持久,安全可靠,复发率低。     

我院高血压病268例中医辨证分型治疗情况调查

目的:调查马鞍山地区中医辨证分型治疗高血压病的情况.方法:对马鞍山市中医医院2002年3月-2004年3月采用中医辨证分型治疗的高血压病患者268例进行统计分析,观察其分别特点及中医药辨证分型治疗对血压控制及不良反应发生情况.结果:肝肾亏虚者及肝肾亏虚夹瘀者的年龄与性别比例上与阴虚阳亢者及肝火亢盛者不同,特别是年龄方面略高于阴虚阳亢者及肝火亢盛者.各证型在改服中药后,血压均较服西药时有明显下降,P＜0.01;改服中药控制血压,使药物不良反应发生率由平均33.95%下降到4.11%;服用中西药物达到最佳血压水平的比率明显不同,服用中药好于西药(P＜0.01).结论:中医药辨证分型治疗可有效干预高血压病进展.     

噻托溴铵粉联合布地奈德福莫特罗吸入治疗支气管哮喘慢性阻塞性肺疾病重叠综合征的短期疗效

目的观察噻托溴铵粉吸入剂（思力华）联合布地奈德福莫特罗（信必可）吸入治疗支气管哮喘慢性阻塞性肺疾病重叠综合征的短期疗效。方法将152例支气管哮喘慢性阻塞性肺疾病重叠综合征患者随机分为试验组（80例）和对照组（72例）。在一般治疗基础上,对照组给予信必可吸入;试验组给予思力华联合信必可吸入,疗程均为4周。观察两组治疗效果。结果治疗后,两组肺功能指标均得到改善,试验组第1秒用力呼气容积（FEV1）、第1秒用力呼气容积占用力肺活量（FEV1/FVC）指标高于对照组（P<0.05）;残气量/肺总量（RV/TLC）指标低于对照组（P<0.05）。两组慢性阻塞性肺疾病评分（CAT评分）均降低,试验组更为明显(P<0.05)。两组ACT评分均升高,试验组更明显,组间比较（23±4）分 vs (15±2）分(P<0.05)。两组急性加重次数均减少,试验组更明显(P<0.05)。两组治疗均未出现严重不良反应。患者平均治疗费用试验组同对照组比较,差异无统计学意义(P>0.05)。结论在支气管哮喘慢性阻塞性肺疾病重叠综合征患者治疗中联用思力华和信必可吸入可提高疗效,且治疗费用增加不明显。     

Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma

AIM: To assess effectiveness of alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma (BA). MATERIAL AND METHODS: 65 BA patients with low densitometric parameters of bone tissue density were examined for bone density, basic parameters of Ca-P metabolism and some markers of bone metabolism during 6-month therapy with alphacalcidol (alpha-D3-TEVA) in a dose 0.5-0.75 mcg/day. RESULTS: All the patients after 6 months of therapy experienced pain relief, normalization of calcium-phosphorus metabolism, lower risk of broken bones. Their bone tissue increased its density. CONCLUSION: Alphacalcidol has analgetic and antiresorptive properties. It effectively prevents and treats osteopenic syndrome in patients with bronchial asthma.     

Experience with the use of vilozen in patients with bronchial asthma

The results of the use of vilozen in the treatment of bronchial asthma patients are presented. The efficacy of the drug for asthma of different genesis is demonstrated. Vilozen stimulates functions of cellular immunity and produces a moderate inhibitory effect on phagocytosis function. The drug is contraindicated in the treatment of patients with bacterial infection and pronounced obstructive syndrome.     

健康教育处方对支气管哮喘患者急性发作的影响

目的评价健康教育处方在支气管哮喘防治方面的价值，减少支气管哮喘患者急性发作频率，提高自护能力及其生活质量。方法将88例支气管哮喘患者随机分为对照组45例和试验组43例。对照组住院期间给予常规指导，出院后保持联系。试验组住院期间至出院后制定健康教育处方，随访两年。比较两组支气管哮喘患者急性发作及住院治疗情况。结果试验组患者对哮喘的相关知识，峰流速仪，定量雾化仪及平喘药物的使用等方面明显优于对照组，其哮喘发作频率及年住院率明显低于对照组（P〈0．01）。结论表明对支气管哮喘患者制定全面的健康教育处方，提高患者对哮喘的认知水平，可减少支气管哮喘急性发作次数及再住院率。     

埃索美拉唑治疗支气管哮喘合并胃食管返流临床疗效观察

目的 观察埃索美拉唑治疗支气管哮喘合并胃食管返流(GERD)临床疗效.方法 选自2009年7月至2011年7月收治的58例支气管哮喘合并GERD患者,根据治疗药物的不同分为两组,其中治疗组30例,采用埃索美拉唑联合莫沙比利治疗,对照组28例,采用奥美拉唑联合莫沙比利治疗.观察比较两组治疗前后的支气管哮喘评分和胃食管返流症状评分.结果 两组治疗后支气管哮喘评分和胃食管返流症状评分,与治疗前比较,差异均有统计学意义(P＜0.01);治疗后,治疗组支气管哮喘评分和胃食管返流症状评分降低较对照组更为明显,两组比较差异均有统计学意义(P＜0.01).结论 埃索美拉唑是治疗支气管哮喘合并GERD安全有效的药物.     

基于ACT反馈的延续性护理对支气管哮喘患者肺功能、哮喘发作与治疗依从性的影响

目的探讨基于ACT反馈的延续性护理对支气管哮喘患者肺功能、哮喘发作与治疗依从性的影响。方法选择我院2018年4月至2019年1月收治的支气管哮喘患者100例为研究对象,根据入院顺序将其等分为对照组和试验组,对照组采用常规护理,试验组在对照组基础上采用基于ACT反馈的延续性护理。比较两组患者肺功能指标、哮喘发作次数、再入院次数及治疗依从性。结果试验组第1秒用力呼气容积、呼气峰值流速、第1秒用力呼气量占用力肺活量比值均大于对照组(P<0.05);试验组6个月内哮喘发作次数、再入院次数少于对照组(P<0.05);试验组治疗依从性高于对照组(P<0.05)。结论基于ACT反馈的延续性护理在支气管哮喘患者中应用,能显著改善肺功能、减少哮喘发作次数、提高治疗依从性。     

Churg-Strauss syndrome (AGA) in Japan]

Churg-Strauss syndrome (CSS) is a rare disease belonging to the group of necrotizing vasculitis. With introduction of guideline therapy for bronchial asthma, many patients have enjoyed the benefit regardless their etiology of asthma. Recently, however, there have been multiple case reports of CSS with relation to leukotriene modifiers, leading to a concern of the potential risk association with the development of CSS and the treatment. We have analyzed recent 16 cases of CSS in our group. Twelve cases had been prescribed steroids (7 oral steroid and 5 inhaled steroid) for a treatment of asthma. Three cases had taken leukotriene modifiers. But two of them were under steroid reduction course. It remains unclear what the exact mechanism of this syndrome is, but physicians must be wary for the signs of CSS, particularly in patients with asthma in whom corticosteroids are tapered.     

Exacerbation of associated bronchial asthma in patients with myocardial infarct

During follow-up of 27 patients with previous long-term history of bronchial asthma it has been established that in 7 of them there was aggravation of broncho-pulmonary illness in the late terms of setting in of myocardial infarction (on the 3rd-6th week, or in 30 days, on the average). Typical features in these patients were blood hypereosinophilia reaching 16-24 per cent and parallel development in some of them of clinical manifestations of the postinfarction syndrome such as pericarditis, pleurisy and transitory lung infiltration. It is believed that this spontaneous aggravation of bronchial asthma in late terms of myocardial infarction can be regarded as one of the manifestations of the postinfarction syndrome typical for this clinical condition. Long-action glucocorticoids (metipred) should be prescribed prior to the development of the clinical symptoms of bronchial asthma to this category of patients taking into consideration only the dynamics of blood eosinophil count.     

Differential diagnosis of bronchial asthma

Altogether 792 patients admitted to the hospital with a diagnosis of bronchial asthma were under observation. The diagnosis was confirmed in 513 (64.8%) patients and was not confirmed in 279 patients. Of these, 148 (53.2%) were diagnosed to have chronic obstructive bronchitis, 80 (28.7%) a bronchospastic syndrome coupled with exacerbation of chronic (in 69) or acute pneumonia (in 11). In 25 (9%) patients, the clinical manifestations were associated with cardiac asthma attacks, 14 (5%) had tumors of the bronchi, trachea or metastatic lung lesions which gave rise to the development of the bronchospastic syndrome. Eight (2.8%) patients were diagnosed to have tracheobronchial dyskinesia, 1 primary lung emphysema, 1 hysteria, 1 pulmonary tuberculosis, and 1 a foreign body. Differential diagnosis between bronchial asthma and the bronchospastic syndrome is presented.     

The principles of the organization of individualized treatment for bronchial asthma patients]

The authors relate the principles according to which the individualized treatment of bronchial asthma patients may be organized: the permanent treating physician, active participation of the patient in the process of treatment, flexibility of the individualized complex of treatment measures under constant control of the treatment efficacy. Provide the experience gained with such organization of the treatment of 35 patients with grave bronchial asthma ("schools for bronchial asthma patients").